Conundrums in CINV Prevention and Management

Conundrums in CINV Prevention and Management

Facing Clinical Challenges to Improve Patient Outcomes

Not a member of My prIME? Join now for instant access.

Meeting Overview

Featured experts in supportive care give answers to the toughest questions surrounding treatment of chemotherapy-induced nausea and vomiting at the MASCC 2019 annual meeting in San Francisco.

Date and Location

Saturday, June 22, 2019
12:05 PM – 1:35 PM

Bayview A-B
Hyatt Regency San Francisco
5 Embarcadero Center
San Francisco, California 94111



Saturday, June 22, 2019
12:05 PM – 1:35 PM



San Francisco, California, United States



1.5 AMA PRA Category 1 Credit(s)™

12:05 PM Welcome and Introductions
Eric J. Roeland, MD
12:10 PM Picking the Right Strategy: Guidelines vs Personalized Management
Eric J. Roeland, MD
12:25 PM Q & A
12:30 PM Panel Case Discussion: Tackling Clinical Conundrums in CINV
Led by Chair: Eric J. Roeland, MD
Matti Aapro, MD
Rebecca Clark-Snow, RN, BSN, OCN
Paz Fernandez-Ortega, PhD, MSc, RN, BPsych
1:15 PM prIME Points™
Eric J. Roeland, MD
1:20 PM Ask the Experts
All faculty
1:35 PM Adjourn



  • Eric J. Roeland, MDMassachusetts General Hospital
    Boston, Massachusetts, United States
  • Faculty

  • Matti Aapro, MDMultidisciplinary Oncology Institute
    Clinique de Genolier
    Genolier, Switzerland
  • Rebecca Clark-Snow, RN, BSN, OCNThe University of Kansas Cancer Center
    Westwood, Kansas, United States
  • Paz Fernández Ortega, PhD, MSc, RN, BPsychCatalan Institute of Oncology
    Duran i Reynals Hospital
    Barcelona, Spain

This educational activity is designed to meet the needs of oncologists, hematologists, nurses, and other healthcare professionals involved in the treatment of patients with CINV.

After successful completion of this educational activity, participants should be able to:

  • Evaluate current antiemetic therapies for the prevention and management of chemotherapy-induced nausea and vomiting (CINV)
  • Select optimal antiemetic therapy based on current guidelines and treatment- and patient-related risk factors
  • Identify best practices for management of challenging issues such as delayed CINV, anticipatory nausea and vomiting, and breakthrough CINV

This educational activity is supported by a grant from Helsinn.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology.   Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.

Americans With Disabilities Act

Event staff will be glad to assist you with any special needs (physical, dietary, etc). Please contact us prior to the live event using the contact form.

There is no fee for this activity.


Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.